The Centre de Recherche en Cancerologie de Marseille (CRCM) goal is to develop cutting edge cancer research from the bench to the bedside. Since its creation, the CRCM develops an integrated cancer research program, from basic science to translational medicine and clinical research, which is unique in Marseille. Their main scientific and medical specialities are the molecular basis of oncogenesis, tumor dissemination and host response on the one hand, and the development of innovative therapeutics mostly in breast cancer, pancreatic cancer and malignant hemopathies. All the 19 teams of the CRCM are internationally recognized and affiliated with INSERM, CNRS and Aix-Marseille University.
The Pancreatic Cancer team, directed by Juan Iovanna, at the CRCM, is interested in the molecular aspects of the pancreatic ductal adenocarcinoma development and progression and to improve the current available therapeutic approaches and, more particularly, in developing tools and strategies towards personalized treatments. The team was centered the subjects of interest on three main areas: 1/ signalization and metabolism of the pancreatic cancer cells; 2/ the role of intra-tumoral microenvironment in PDAC carcinogenesis; and finally 3/ on translational medicine by developing an exceptional molecularly and functionally well characterized PDTX collection from 200 patients and a collection of primary organoids. Concerning these last approaches the team focuses on a systematic characterization on DNA, RNA and proteins as well as metabolites and epigenomics modifications. On the other hand, the establishment of a chemogram, by analogy with the antibiogram for microorganisms, allows the identification of the most efficient anticancer drug for a given patient. The main objective of this project is the selection of markers that would predict the evolution and chemotherapeutic sensitivity of tumors, this will be used to choose the most suitable treatment for each patient, which would reduce the costs and chances of error treating patient with drugs for which the tumor is resistant, and finally limiting any potential outside effects.